[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY34018A - Derivados glucósidos y usos de los mismos - Google Patents

Derivados glucósidos y usos de los mismos

Info

Publication number
UY34018A
UY34018A UY0001034018A UY34018A UY34018A UY 34018 A UY34018 A UY 34018A UY 0001034018 A UY0001034018 A UY 0001034018A UY 34018 A UY34018 A UY 34018A UY 34018 A UY34018 A UY 34018A
Authority
UY
Uruguay
Prior art keywords
same
glucoside derivatives
glucoside
derivatives
página
Prior art date
Application number
UY0001034018A
Other languages
English (en)
Inventor
Gregory Raymond Bebernitz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46028035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34018(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY34018A publication Critical patent/UY34018A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

El presente invento proporciona un compuesto de la fórmula I un método para fabricar los compuesto del invento, y sus usos terapéuticos. El presente invento además proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica.
UY0001034018A 2011-04-14 2012-04-12 Derivados glucósidos y usos de los mismos UY34018A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161475476P 2011-04-14 2011-04-14

Publications (1)

Publication Number Publication Date
UY34018A true UY34018A (es) 2012-11-30

Family

ID=46028035

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034018A UY34018A (es) 2011-04-14 2012-04-12 Derivados glucósidos y usos de los mismos

Country Status (25)

Country Link
US (2) US8614195B2 (es)
EP (1) EP2697217B1 (es)
JP (1) JP5908973B2 (es)
KR (1) KR20140027250A (es)
CN (1) CN103748090B (es)
AP (1) AP2013007179A0 (es)
AR (1) AR086086A1 (es)
AU (1) AU2012241427B2 (es)
BR (1) BR112013026257A2 (es)
CA (1) CA2832958A1 (es)
CL (1) CL2013002973A1 (es)
CO (1) CO6781541A2 (es)
CR (1) CR20130530A (es)
CU (1) CU20130139A7 (es)
EA (1) EA201391525A1 (es)
ES (1) ES2621007T3 (es)
IL (1) IL228771A0 (es)
MA (1) MA35032B1 (es)
MX (1) MX2013011927A (es)
PE (1) PE20141039A1 (es)
SG (1) SG194463A1 (es)
TN (1) TN2013000413A1 (es)
TW (1) TW201245219A (es)
UY (1) UY34018A (es)
WO (1) WO2012140597A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5876570B2 (ja) * 2011-06-01 2016-03-02 グリーン・クロス・コーポレイションＧｒｅｅｎ Ｃｒｏｓｓ Ｃｏｒｐ． Ｓｇｌｔ２阻害剤としての新規のジフェニルメタン誘導体
WO2014161836A1 (en) 2013-04-04 2014-10-09 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
US10011627B2 (en) 2013-09-09 2018-07-03 Youngene Therapeutics Co., Ltd C-aryl glucoside derivative, preparation methods thereof, and medical applications thereof
CA2889699C (en) 2013-09-27 2017-06-06 Sunshine Lake Pharma Co., Ltd. Glucopyranosyl derivatives and their uses in medicine
PL3862003T3 (pl) 2013-12-17 2024-04-02 Boehringer Ingelheim Vetmedica Gmbh Inhibitor sglt2 do zastosowania w leczeniu zaburzenia metabolicznego u zwierząt kotowatych
CA2932674C (en) 2014-01-23 2023-01-24 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in canine animals
MX2016012705A (es) 2014-04-01 2016-12-16 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de trastornos metabolicos en animales equinos.
US10555958B2 (en) 2014-09-25 2020-02-11 Boehringer Ingelheim Vetmedica Gmbh Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
BR112018003749B1 (pt) 2015-08-27 2023-10-31 Boehringer Ingelheim Vetmedica Gmbh Composições farmacêuticas líquidas compreendendo inibidores sglt-2, kit de peças e processo para a produção da composição farmacêutica líquida
CN105294624B (zh) * 2015-11-16 2018-01-12 山东罗欣药业集团股份有限公司 一种达格列净的制备方法
CN108203432B (zh) * 2016-12-20 2021-03-02 宜昌东阳光长江药业股份有限公司 吡喃葡萄糖基衍生物及其在医药上的应用
TW201834663A (zh) * 2017-03-03 2018-10-01 瑞士商諾華公司 Sglt1/2抑制劑之給藥方案
WO2020242253A1 (ko) * 2019-05-30 2020-12-03 동아에스티 주식회사 Sglt-2 억제제인 신규 엠파글리플로진 유도체
CN113330017B (zh) * 2019-12-19 2023-01-31 上海研健新药研发有限公司 一种SGLTs抑制剂的纯化方法及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
HU229581B1 (en) 1999-08-31 2014-02-28 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6627611B2 (en) * 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
UA72586C2 (en) 2000-03-17 2005-03-15 Kissei Pharmaceutical Glucopyranozyloxybenzylbenzene derivatives, a pharmaceutical composition containing these derivatives, and intermediary compounds for obtaining said derivatives
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
KR100647204B1 (ko) 2000-09-29 2006-11-17 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실옥시벤질벤젠 유도체 및 그것을 함유하는의약조성물
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
WO2003020737A1 (en) 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
JP4222450B2 (ja) * 2003-03-14 2009-02-12 アステラス製薬株式会社 Ｃ−グリコシド誘導体又はその塩
AU2003902263A0 (en) 2003-05-12 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
BRPI0410779A (pt) 2003-05-20 2006-06-27 Novartis Ag heterociclos de n-acil nitrogênio como ligantes de receptores ativados por proliferador de peroxissoma
CA2549017A1 (en) 2003-08-01 2005-02-10 Mona Patel Substituted indazole-o-glucosides
EP1660509B1 (de) 2003-08-26 2009-02-04 Boehringer Ingelheim International GmbH Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
NZ549629A (en) 2004-03-04 2010-06-25 Kissei Pharmaceutical Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
CA2557320C (en) 2004-03-04 2013-02-05 Kissei Pharmaceutical Co., Ltd. Fused heterocyclic derivatives for prevention or treatment of hyperglycemia
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JP2008508213A (ja) 2004-07-27 2008-03-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄ−グルコピラノシル−フェニル置換環状体、そのような化合物を含有する医薬品、それらの使用及びその製造方法
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2588963C (en) 2004-11-18 2013-06-25 Kissei Pharmaceutical Co., Ltd. 1-substituted-3-.beta.-d-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
TW201000494A (en) * 2008-02-13 2010-01-01 Sanofi Aventis Novel aromatic fluoroglycoside derivatives, medicaments comprising these compounds and use thereof
WO2010128152A1 (en) * 2009-05-07 2010-11-11 Novartis Ag Fused heterocyclic c-glycosides for the treatment of diabetes
US8163704B2 (en) * 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof

Also Published As

Publication number Publication date
EP2697217B1 (en) 2016-12-28
PE20141039A1 (es) 2014-08-30
CL2013002973A1 (es) 2014-03-07
AU2012241427A1 (en) 2013-10-31
CN103748090A (zh) 2014-04-23
CN103748090B (zh) 2016-09-14
KR20140027250A (ko) 2014-03-06
MX2013011927A (es) 2013-11-01
CA2832958A1 (en) 2012-10-18
TN2013000413A1 (en) 2015-03-30
AR086086A1 (es) 2013-11-20
EA201391525A1 (ru) 2014-02-28
WO2012140597A1 (en) 2012-10-18
US20120264700A1 (en) 2012-10-18
US20130018005A1 (en) 2013-01-17
CO6781541A2 (es) 2013-10-31
AU2012241427B2 (en) 2014-11-20
IL228771A0 (en) 2013-12-31
CR20130530A (es) 2014-02-04
AP2013007179A0 (en) 2013-10-31
CU20130139A7 (es) 2014-01-29
JP2014511874A (ja) 2014-05-19
MA35032B1 (fr) 2014-04-03
TW201245219A (en) 2012-11-16
JP5908973B2 (ja) 2016-04-26
ES2621007T3 (es) 2017-06-30
BR112013026257A2 (pt) 2019-09-24
US8614195B2 (en) 2013-12-24
SG194463A1 (en) 2013-12-30
EP2697217A1 (en) 2014-02-19

Similar Documents

Publication Publication Date Title
UY34018A (es) Derivados glucósidos y usos de los mismos
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
UY34271A (es) Anticuerpos anti-tie2 y usos de los mismos
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
UY34538A (es) Heteroarilos y usos de los mismos
UY34876A (es) Anticuerpos anti-egfr y usos de los mismos
UY34502A (es) Arilos y heteroarilos bicíclicos inhibidores de los canales de sodio
CR20150524A (es) Compuestos de heteroarilo y sus usos
CR20140259A (es) Compuestos novedosos de benzopirano, composiciones y usos de los mismos
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
UY33970A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
UY33946A (es) Derivados de c4-monometil triterpenoides y sus métodos de uso
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
UY33925A (es) Inhibidores tricíclicos de quinasas
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
GT201500069A (es) Piridinonas bicìclicas novedosas
UY34536A (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
NI201400079A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY34797A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
UY34603A (es) Anticuerpos anti-asic-1 y usos de los mismos
UY34034A (es) Triazolopiridinas
UY33984A (es) Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020